Hanyang UniversityOpportunity Contact
James Noh, CEO
Seoul, South Korea

Hanyang University Website
TherapeuticPreclinical Pharmalicensing.com

Development of customized treatments for neurodegenerative disease focused on immune-inflammatory modulation through novel use of NCKAP1 in the regulation of microglial cell dysfunction.

Introduction/Background
We identify a cell-permeable peptide, dNP2, which efficiently delivers proteins into mouse and human T cells, as well as various tissues. Moreover, it enters the brain tissue and resident cells through blood vessels by penetrating the tightly organized blood–brain barrier. Then, we developed cytoplasmic domain of CTLA-4 (ctCTLA-4) peptide without its ligand interacting domain by conjugating BBB-penetrating peptide, dNP2 (dNP2-ctCTLA-4). We found that this dNP2-ctCTLA-4 could be able to induce Foxp3 expression in T cells which is important marker for regulatory T cells dependent on TGF-β. Moreover, dNP2-ctCTLA-4 treatment in vivo remarkably controls EAE progression by increase of Treg cells, which assures prolonged suppression of disease relapse.


Description of Technology

Neurodegenerative diseases (ND), including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD), have emerged as a major public health problem worldwide with ageing. However, the complexity of ND in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents.

Research plans that integrate new drug discoveries are urgently needed, including those based on novel and reliable biomarkers that reflect not only clinical phenotype, but also genetic and neuroimaging information. Therapeutic strategies of personalized medicine could be set as new directions for developing effective drugs for ND including AD, ALS, and PD.

The Korean AD Research Platform Initiative based on immune-inflammatory biomarkers (K-ARPI) has recently launched a strategy to develop novel biomarkers to identify a subpopulation of patients with AD and to develop new drug candidates for delaying the progression of AD by modulating toxic immune-inflammatory response.

We focused on microglial phagocytosis regulation through actin motility related proteins, such as NCK-associated protein 1 (NCKAP1), were selected as promising targets to modulate neuro-inflammation.

Development of customized treatments for neurodegenerative disease focused on immune-inflammatory modulation through novel use of NCKAP1 in the regulation of microglial cell dysfunction.

This can establish a new pathogenesis and strategy as a biological novel treatment target that identifies new phagocytic regulation factors of microglial cells that induce the termination of chronic inflammation in neurodegenerative diseases.

Figure 1. Schematic summary of the decision platform of the K-ARPI.
K-ARPI: Korean AD Research Platform Initiative based on immune-inflammatory biomarkers

Type of Business Relationship Sought
Out license, Partnership


COGNIS GROUP MISSION
The pace of change in our world continues to accelerate.  We all see this play out on the grand stage daily:  new diseases, warming oceans, increased hurricanes and fires, supply shortages, changes in social behaviors, more focus on alternative energies; the list goes on and on.  
We all have a role in proactively preparing for the ongoing shifts that we will encounter.  Our passionate team at Cognis Group is focused on helping you navigate innovation potential for the greatest collective benefits to people, the planet, and long term profits.

For more information, contact us:
info@cognisgroup.com
US: +1 303 709 3157
UK: +44 1904 435190